Real-life Performance Evaluation of the LiFlow X-ray Platform

ConditionSolid Cancers
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Angers

About this trial

The thoraco-abdomino-pelvic (TAP) scanner is crucial for assessing and monitoring solid cancers. However, advancements in scanner technology have led to a significant increase in data volume, from 100 images per exam 20 years ago to 2,000 today. The rising number of cancer cases and treatments requiring closer monitoring further strain the workload, prolonging interpretation time and causing delays in therapeutic management and adjustments. The limited number of radiologists contributes to this saturation, increasing the risk of missing metastatic lesions, especially in the lungs, liver, bones, peritoneum, and lymph nodes. The RECIST 1.1 criteria, introduced 15 years ago for standardized follow-up, are useful but time-consuming to implement, resulting in only a small fraction of oncology CT reports using them.

Eligibility criteria

Qualifiers

TAP (thoraco-abdomino-pelvic) scans

Age > 18 years

Disqualifiers

Examination of imperfect quality due to movement or breathing,

Inability to inject contrast medium or incomplete injection

refusal to use data

Trial design

Treatments tested in this trial

  • Radiologist interpretation

Treatment groups

No treatment groups listed

Locations

This trial has no locations

Sponsors and collaborators